TNFRSF4 and cancer: OX40 has been considered as a drug target to enhance or inhibit T cell responses for over 20 years32, in a number of pathological conditions, spanning from allergy and autoimmune diseases to cancer, which are characterized by extremely different inflammatory conditions11,33,34.